Form 4: Marinus Pharmaceuticals Chairman and CEO Reports Changes in Beneficial Ownership Following Merger

Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, reports changes in beneficial ownership of common stock and derivative securities following the merger with Immedica Pharma AB.

Summary

• Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On August 14, 2024, Braunstein purchased 5,933 shares of common stock at a weighted-average price ranging from $1.09 to $1.10.
• Braunstein voluntarily paid the issuer $52,582.55 due to unintentional matching transactions for Section 16(b) reporting purposes, related to a purchase on August 14, 2024, matched against a sale on February 16, 2024, under a Rule 10b5-1 plan.
• On December 29, 2024, Marinus Pharmaceuticals entered into a merger agreement with Immedica Pharma AB.
• As a result of the merger, Braunstein's 125,064 shares of common stock and 179,536 shares underlying Restricted Stock Units (RSUs) were acquired at $0.55 per share.
• Outstanding out-of-the-money stock options were terminated without payment.
• The transactions occurred on February 11, 2025, following the merger's effective time.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports factual changes in ownership due to a merger. While the termination of stock options without payment could be seen as negative for the reporting person, the overall tone is objective and descriptive.

Positives

• Braunstein voluntarily rectified unintentional matching transactions by paying $52,582.55 to the issuer.

Negatives

• Out-of-the-money stock options held by Braunstein were terminated without any payment as a result of the merger.

Risks

• The termination of stock options without payment could be perceived negatively by the reporting person.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

This filing reflects the completion of a merger transaction, which is a common occurrence in the pharmaceutical industry as companies seek to consolidate resources, expand product portfolios, or gain access to new markets. Mergers and acquisitions can significantly impact the ownership structure and executive compensation within a company, as evidenced by the changes in beneficial ownership and the termination of stock options.

Comparison to Industry Standards

• Merger transactions in the pharmaceutical industry often involve similar arrangements for stock options and RSUs, with cash payments for vested equity and termination of out-of-the-money options.
• The $0.55 per share offer price would need to be compared to the company's valuation metrics prior to the announcement to assess the fairness of the deal.
• Similar transactions involving companies like Alder BioPharmaceuticals (acquired by Lundbeck) and Array BioPharma (acquired by Pfizer) involved comparable treatment of equity awards.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• The CEO's stock options were terminated, impacting his potential future gains from those options.

Key Dates

Keywords

Form 4, beneficial ownership, merger, Marinus Pharmaceuticals, Immedica Pharma AB, stock options, common stock, RSUs, Section 16(b), Braunstein